New hope for advanced breast cancer: experimental drug HLD-0117 enters human testing
NCT ID NCT07524855
First seen Apr 15, 2026 · Last updated May 16, 2026 · Updated 2 times
Summary
This early-stage study tests a new drug called HLD-0117 in about 33 women with a type of advanced breast cancer (ER-positive) that has spread and stopped responding to standard treatments. The main goals are to check the drug's safety and find the right dose. Researchers will also watch for signs that the drug shrinks tumors or slows the cancer's growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Florida Cancer Specialists
RECRUITINGSarasota, Florida, 34231, United States
-
NEXT Oncology
RECRUITINGFairfax, Virginia, 22031, United States
-
SCRI Oncology Partners
RECRUITINGNashville, Tennessee, 37203, United States
Conditions
Explore the condition pages connected to this study.